Carregant...
Carregant...

Vés al contingut (premeu Retorn)

Informed choice of composite end points in cardiovascular trials

Autor
Gomez, G.; Gomez, M.; Dafni, U.
Tipus d'activitat
Article en revista
Revista
Circulation-Cardiovascular Quality and Outcomes
Data de publicació
2014-01-01
Volum
7
Número
1
Pàgina inicial
170
Pàgina final
178
DOI
https://doi.org/10.1161/CIRCOUTCOMES.113.000149 Obrir en finestra nova
Projecte finançador
ANALISIS DE SUPERVIVENCIA PARA MULTIPLES EVENTOS CON PATRONES DE CENSURA COMPLEJOS
Métodos avanzados en estudios de seguimiento: diseño de ensayos clínicos, datos longitudinales y censura en un intervalo
Resum
A composite end point is often used as the primary end point to assess the efficacy of a new treatment in randomized clinical trials. In cardiovascular trials, the often rare event of the relevant primary end point (individual or composite), such as cardiovascular death, myocardial infarction, or both, is combined with a more common secondary end point, such as target lesion revascularization, with the aim to increase the statistical power of the study. Gomez and Lagakos developed statistical me...
Paraules clau
Asymptotic Relative Efficiency, Cardiovascular Drugs, Clinical Trials, Randomized, Composite End Point, Logrank Test, Acute Myocardial-infarction, Placebo-controlled Trial, Acute Coronary Syndrome, Clinical-trials, Heart-failure, Epidemiology Strobe, Randomized-trials, Double-blind, Issues, Prevention
Grup de recerca
GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica

Participants